Last reviewed · How we verify
TPOXX — Competitive Intelligence Brief
marketed
Orthopoxvirus protein synthesis inhibitor
Orthopoxvirus p37 protein
Infectious Disease / Virology
Small molecule
Live · refreshed every 30 min
Target snapshot
TPOXX (TPOXX) — SIGA Technologies. TPOXX inhibits orthopoxvirus protein synthesis by blocking viral RNA polymerase, preventing viral replication.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TPOXX TARGET | TPOXX | SIGA Technologies | marketed | Orthopoxvirus protein synthesis inhibitor | Orthopoxvirus p37 protein |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Orthopoxvirus protein synthesis inhibitor class)
- SIGA Technologies · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TPOXX CI watch — RSS
- TPOXX CI watch — Atom
- TPOXX CI watch — JSON
- TPOXX alone — RSS
- Whole Orthopoxvirus protein synthesis inhibitor class — RSS
Cite this brief
Drug Landscape (2026). TPOXX — Competitive Intelligence Brief. https://druglandscape.com/ci/tpoxx. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab